Research Topics
| Robert BelsheSummaryAffiliation: Saint Louis University Country: USA Publications
| Collaborators
|
Detail Information
Publications
A century of influenza prevention in St. LouisRobert B Belshe
Division of Infectious Diseases, Allergy and Immunology Department of Internal Medicine at Saint Louis University School of Medicine, USA
Mo Med 109:119-23. 2012..Closing schools, churches, theaters, and other public meeting places reduced the severity of the pandemic in St. Louis. The benefits of contemporary influenza vaccines to prevent influenza and economic disruption are summarized...- Efficacy results of a trial of a herpes simplex vaccineRobert B Belshe
Division of Infectious Diseases, Allergy, and Immunology, Saint Louis University, St Louis, MO 63104, USA
N Engl J Med 366:34-43. 2012..Efficacy was not observed in men or HSV-1 seropositive women... - Current status of live attenuated influenza virus vaccine in the USRobert B Belshe
Health Science Center, Division of Infectious Diseases, Saint Louis University, 3035 Vista at Grand Blvd, St Louis, MO 63110, USA
Virus Res 103:177-85. 2004..Effectiveness measures, including protection against febrile otitis media and visits to the doctor were demonstrated. Live attenuated vaccine provides a significant new tool to help prevent influenza... - Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 yearsRobert B Belshe
Center for Vaccine Development, Saint Louis University School of Medicine, St Louis, MO 63110, USA
Clin Infect Dis 39:920-7. 2004.... - Serum antibody responses after intradermal vaccination against influenzaRobert B Belshe
Department of Internal Medicine, Division of Infectious Diseases and Immunology, Saint Louis University, St Louis, MO 63110, USA
N Engl J Med 351:2286-94. 2004..If found to be safe and immunogenic, reduced doses of influenza vaccine given by the intradermal route could increase the number of available doses of vaccine... - Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young childrenRobert B Belshe
Saint Louis University, St Louis, Missouri 63110, USA
J Infect Dis 190:2096-103. 2004..Both vaccines were immunogenic, and antibody responses were similar between the monovalent groups and the combination group. Combined RSV/PV3 vaccine is feasible for simultaneous administration, and further studies are warranted... - Live attenuated versus inactivated influenza vaccine in infants and young childrenRobert B Belshe
Saint Louis University Health Sciences Center, St Louis, USA
N Engl J Med 356:685-96. 2007..S. advisory bodies. To evaluate alternative vaccine approaches, we compared the safety and efficacy of intranasally administered live attenuated influenza vaccine with those of inactivated vaccine in infants and young children... - Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccineRobert Belshe
Division of Infectious Diseases and Immunology, Saint Louis University, 3635 Vista Avenue FDT 8N, St Louis, MO 63110, USA
Expert Rev Vaccines 3:643-54. 2004..In the future it is expected that additional studies will support a broadening of the age range for use with the LAIV to prevent influenza in children and adults... - Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adultsRobert B Belshe
Saint Louis University Medical Center, St Louis, MO 63110, United States
Vaccine 25:6755-63. 2007..ID route was not superior to IM vaccine at inducing antibodies. ID vaccine induced significantly more local inflammatory response than IM vaccine... - Translational research on vaccines: influenza as an exampleR B Belshe
Division of Infectious Diseases and Immunology, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA
Clin Pharmacol Ther 82:745-9. 2007..The pipeline for new influenza vaccines is robust, and recent investment by government and industry in newer vaccines will bring several new products to clinical use... - Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of ageRobert B Belshe
Saint Louis University Medical Center, St Louis, MO, USA
Vaccine 26:D10-6. 2008..Hospitalizations and medically significant wheezing were increased in children 6-11 and 6-23 months of age who received LAIV, respectively, but were not increased in children 2-5 years of age... - Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarityRobert B Belshe
Saint Louis University Health Science Center, St Louis, MO 63104, USA
Vaccine 28:2149-56. 2010.... - The need for quadrivalent vaccine against seasonal influenzaRobert B Belshe
Saint Louis University School of Medicine, USA
Vaccine 28:D45-53. 2010.... - Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variantRobert B Belshe
Division of Infectious Diseases and Immunology, Saint Louis University School of Medicine, St Louis, Missouri 63104, USA
J Infect Dis 203:666-73. 2011..Recent H5 disease has been caused by antigenically divergent H5 viruses, including A/Indonesia/05/2005 (a clade 2 H5 virus)... - Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalentRobert B Belshe
Division of Infectious Diseases and Immunology, Saint Louis University, 3635 Vista Avenue FDT 8N, St Louis, MO 63110, USA
Immunol Allergy Clin North Am 23:745-67. 2003..For children aged 5 to 8 years, two doses are recommended the first year they are immunized with CAIV-T to ensure protection against all strains contained in the vaccine. Thereafter, a single annual revaccination is sufficient... - Dose-dependent neutralizing-antibody responses to vacciniaRobert B Belshe
Center for Vaccine Development, Saint Louis University School of Medicine, St Louis, Missouri 63110, USA
J Infect Dis 189:493-7. 2004..Larger lesion size and fever after vaccination were associated with significantly higher neutralizing-antibody titers after vaccination... - Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months oldRobert B Belshe
Division of Infectious Diseases and Immunology, Saint Louis University, St Louis, Missouri, USA
J Infect Dis 189:462-70. 2004..PIV3-cp45 vaccine was safe and immunogenic in seronegative children and should be evaluated for efficacy in a phase 3 field trial... - Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccineR B Belshe
Department of Medicine, Saint Louis University, St Louis, MO 63110, USA
J Infect Dis 181:1133-7. 2000..Any serum HAI antibody or any nasal wash IgA antibody was correlated with significant protection from H1N1 infection as indicated by vaccine-virus shedding, and high efficacy against H1N1 challenge was demonstrated... - Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteersR B Belshe
Department of Internal Medicine, Saint Louis University School of Medicine and St Louis Veterans Affairs Medical Center, 3635 Vista Ave FDT 8N St Louis, MO 63110, USA
J Infect Dis 183:1343-52. 2001.... - Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and childrenR B Belshe
Department of Medicine, Saint Louis University, St Louis, Mo 63110 0250, USA
Philos Trans R Soc Lond B Biol Sci 356:1947-51. 2001..General use of CAIV-T has the potential to significantly reduce the impact of influenza in children and adults... - Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of ageRobert B Belshe
Saint Louis University Health Science Center, St Louis, MO, USA
Influenza Other Respi Viruses 4:141-5. 2010..LAIV is currently approved in the United States, South Korea and Hong Kong for individuals 2-49 years of age... - Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in childrenDavid I Bernstein
Division of Infectious Diseases, Cincinnati Children s Hospital Medical Center, OH, USA
Pediatr Infect Dis J 22:28-34. 2003..The cold-adapted, trivalent influenza vaccine (CAIV-T) may become an option for annual vaccination. However, there is little information regarding the immune response to repeated immunization with CAIV-T... - Response to smallpox vaccine in persons immunized in the distant pastSharon E Frey
Department of Medicine, Saint Louis University School of Medicine and National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Unit, MO, USA
JAMA 289:3295-9. 2003..Fewer adverse reactions were observed in this study of non-naive participants when compared with events in vaccinia-naive participants, which may be due to immunologic memory... - Dose-related effects of smallpox vaccineSharon E Frey
Department of Medicine, National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Unit, Saint Louis University School of Medicine, St. Louis, USA
N Engl J Med 346:1275-80. 2002..The development of vesicular skin lesions after vaccination correlates with the induction of the antibody and T-cell responses that are considered essential for clearing vaccinia virus infections... - Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challengeSharon E Frey
Department of Medicine, Saint Louis University School of Medicine and National Institute of Allergy and Infectious Diseases Vaccine Treatment and Evaluation Unit, 1100 S Grand Blvd DRC 8, St Louis, MO 63104, USA
Vaccine 25:8562-73. 2007..IMVAMUNE vaccination prior to Dryvax reduced virus replication at the Dryvax site, decreased the size of the primary cutaneous lesion, and decreased the time to healing but did not completely ameliorate the immune response... - Stability of undiluted and diluted vaccinia-virus vaccine, DryvaxFrances K Newman
Saint Louis University, St Louis, Missouri, USA
J Infect Dis 187:1319-22. 2003.... - Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infectionGeoffrey J Gorse
St Louis Department of Veterans Affairs Medical Center, St Louis University, St Louis, MO 63110, USA
Vaccine 22:383-97. 2004..Sera from vaccine recipients bound to HIV-1-infected cells, but at levels lower than did infected patient sera... - Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccineFrances K Newman
Saint Louis University Vaccine Treatment and Evaluation Unit, St Louis, Missouri 63110, USA
J Clin Microbiol 41:3154-7. 2003..Therefore, the more sensitive, specific, and reproducible plaque neutralization assay for the detection of antibody to vaccinia virus is the method using a 15-h-incubation time and freshly sonicated vaccinia virus... - Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adultsSharon E Frey
Saint Louis University School of Medicine, Division of Infectious Diseases and Immunology, St Louis, MO 63104, USA
Vaccine 28:6367-73. 2010..We describe the first in humans clinical trial of this prophylactic HCV vaccine... - Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteinsRanjit Ray
Department of Internal Medicine and Vaccine and Treatment Evaluation Unit, Saint Louis University, St Louis, Missouri, USA
J Infect Dis 202:862-6. 2010..Neutralizing serum samples had increased affinity levels and displayed >2-fold higher specific activity levels to well-characterized epitopes on E1/E2, especially to the hypervariable region 1 of E2... - Antibody responses to vaccinia membrane proteins after smallpox vaccinationSteven J Lawrence
Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO 63110, USA
J Infect Dis 196:220-9. 2007..Vaccinia virus (VV) membrane proteins are candidates for orthopoxvirus subunit vaccines and potential targets for therapeutic antibodies. Human antibody responses to these proteins after VV vaccination have not been well characterized... - Clinical responses to undiluted and diluted smallpox vaccineSharon E Frey
Department of Medicine, National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Unit, Saint Louis University School of Medicine, St. Louis, USA
N Engl J Med 346:1265-74. 2002..0) pfu per milliliter (approximately 10,000 pfu per dose) and induce local viral replication and vesicle formation in more than 97 percent of persons... - The immunogenetics of smallpox vaccinationSamuel L Stanley
Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
J Infect Dis 196:212-9. 2007.... - The genetic archaeology of influenzaDaniel F Hoft
Division of Infectious Disease and Immunology, Department of Internal Medicine and Molecular Microbiology, Saint Louis University, St. Louis, USA
N Engl J Med 351:2550-1. 2004 - Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functionsGetahun Abate
Department of Internal Medicine, Saint Louis University, St. Louis, Missouri 63110, USA
J Infect Dis 192:1362-71. 2005..CFSE-based flow-cytometric assays will be useful in evaluating cell-mediated immune responses induced by new smallpox vaccines... - The origins of pandemic influenza--lessons from the 1918 virusRobert B Belshe
Division of Infectious Diseases and Immunology, Department of Internal Medicine, Saint Louis University, St. Louis, USA
N Engl J Med 353:2209-11. 2005 - Poxvirus zoonoses--putting pocks into contextSharon E Frey
Division of Infectious Diseases and Immunology, Saint Louis University, St. Louis, USA
N Engl J Med 350:324-7. 2004 - Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adultsDavid van Duin
Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06520, USA
J Infect Dis 195:1590-7. 2007..We examined whether CD80 and CD86 expression vary with aging and predict response to the trivalent inactivated influenza vaccine... - Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccinationKenneth M Zangwill
School of Medicine, UCLA Harbor-UCLA Medical Center, Torrance, CA, USA
Pediatr Infect Dis J 23:189-97. 2004.... - Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160Deborah Lee
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
J Infect Dis 190:903-7. 2004..4, P =.1, and P =.7, respectively). Persons who acquire HIV-1 infection while enrolled in HIV-1 vaccine trials can be successfully followed after infection, to determine whether vaccines alter the course of HIV-1 infection... - Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccinationJeffrey S Kennedy
Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
J Infect Dis 190:1286-94. 2004..Postvaccination cell-mediated immune (CMI) responses have not been compared by use of controlled trials in previously vaccinated (vaccinia-nonnaive) and nonvaccinated (vaccinia-naive) individuals... - Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged childrenPedro A Piedra
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030, USA
Pediatrics 110:662-72. 2002..To provide additional information on the safety of trivalent, cold-adapted influenza vaccine (CAIV-T) in children... - A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infantsRuth A Karron
Pediatr Infect Dis J 22:394-405. 2003..ca revertants were not detected. CONCLUSIONS: The cp-45 vaccine is appropriately attenuated and immunogenic in infants as young as 1 month of age. Further development of this vaccine is warranted... - Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infantsRuth A Karron
Center for Immunization Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
J Infect Dis 191:1093-104. 2005..Recombination technology can be used to create live attenuated respiratory syncytial virus (RSV) vaccines that contain combinations of known attenuating mutations... - Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United StatesBryan R Luce
United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
Vaccine 26:2841-8. 2008.... - Live attenuated intranasal influenza vaccineRobert B Belshe
Vaccine 20:3429-30. 2002 - Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlersShabir A Madhi
University of the Witwatersrand Medical Research Council Respiratory and Meningeal Pathogens Research Unit, South Africa
Vaccine 24:2432-9. 2006..This study examined the transmissibility between young children of an intranasally administered live attenuated human parainfluenza virus type 3 (HPIV3)-cp45 vaccine candidate... - The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccinesPeter F Wright
Vanderbilt University, Nashville, TN, USA
Vaccine 25:7372-8. 2007..The impact of RSV during this surveillance will inform the design of future efficacy studies with RSV vaccines... - The burden of influenza and strategies for preventionRobert B Belshe
St. Louis University, St. Louis, USA
Manag Care 16:2-6; discussion 17-9. 2007